Despitemammalian cell cultures being the preferred manufacturing approach forbiologics, recent advances in microbial fermentation have enabled thedevelopment of versatile biomanufacturing systems, which are both robust andcost friendly. Presently, a number of service provider companies claim to offerend-to-end solutions, ranging from product development to commercialproduction, for microbial biologics. Given the obvious advantages ofoutsourcing, drug developers are likely to continue relying on contract serviceproviders for various aspects of their respective microbial biologicdevelopment programs.
To order this 320+ page report, which features 150+ figuresand 150+ tables, please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
TheUSD 9.3 billion (by 2030) financial opportunity within the microbialbiomanufacturing market has been analyzed across the following segments:
§ Type of Product
§ API
§ FDF
§ Typeof Biologic
§ Proteins
§ Enzymes
§ GrowthHormones
§ Antibodybased Drugs
§ Others(plasmid DNA, probiotics, microbiome-based biologics)
§ Type of Microbial Expression System
§ Bacteria
§ Yeast
§ Others(Algae and fungi)
§ Scaleof Operation
§ Commercial
§ Preclinical/ Clinical
§ Typeof End User
§ SmallCompanies
§ Mid-sizedCompanies
§ Large/ Very Large Companies
§ KeyGeographical Regions
§ NorthAmerica
§ Europe
§ AsiaPacific
§ MiddleEast and North Africa
§ LatinAmerica
The MicrobialContract Biomanufacturing Market, 2020-2030 report features thefollowing companies, which we identified to be key players in this domain:
§ AGCBiologics
§ Aldevron
§ BioVectra
§ EirGenix
§ Etinpro
§ Eurogentec
§ NorthwayBiotechpharma
§ OlogyBioservices
§ PortonBiopharma
§ StelisBiopharma
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Company Competitiveness Analysis
6. Company Profiles
7. Recent Partnerships
8. Recent Expansions
9. Microbialfermentation technology platforms
10. Assessment of Relative Competition and Growth
11. Make versus Buy Decision Making Framework
12. Big PharmaInitiatives in Microbial Biomanufacturing
13. Case study: comparison of small molecule and large
14. Market Sizing and Opportunity Analysis
15. Impact of covid-19 pandemic on microbial contractbiomanufacturing market
16. Swot Analysis
17. Conclusion Appendix 3: List of Companies andOrganizations
18. Interview Transcripts
19. Appendix 1: Tabulated Data
20. Appendix 2: List of Companies and Organizations
Topurchase a copy, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
Contact Details
GauravChaudhary
+1(415) 800 3415
gaurav.chaudhary@rootsanalysis.com
